299 results about "Cellular viability" patented technology

A method of determining information about cell viability and other characteristics relating to cell membrane permeability is disclosed. The method involves determining the effect of a cell on current flow and relating that effect to a known standard which standard may be a known healthy cell and thereby deducing the viability of the cell being tested. The cells being tested can be subjected to different environmental conditions such as surrounding chemicals, temperature, pH and pressure to determine the effects of such conditions on cell viability and / or cell permeability. The cell being tested can be in a cell suspension, grown on s ubstarte, in tissue in vitro or in tissue in vivo. The method provides substantially instantaneous results and need not include the use of dyes or other markers.

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and / or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

We introduce a new method for implementing cell-based assays and long-term cell culture. The method is based on digital microfluidics (DMF) which is used to actuate nanoliter droplets of reagents and cells on a planar array of electrodes. DMF method is sutable for assaying and culturing both cells in suspension and cells grown on surface (adherent cells). This method is advantageous for cell culture and assays due to the automated manipulation of multiple reagents in addition to reduced reagent use and analysis time. No adverse effects of actuation by DMF were observed in assays for cell viability, proliferation, and biochemistry. These results suggest that DMF has great potential as a simple yet versatile analytical tool for implementing cell-based assays and cell culture on the microscale.

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and / or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility.

The present invention relates to methods and devices for maintaining cellular viability and function for therapeutic purposes. The invention provides methods and devices for maintaining the proliferative and developmental potential of cellular preparations by protecting the from physical and physiological damage during storage, preparation, and delivery to a site (e.g., a tissue site). The invention also provides methods and devices for evaluating tissues and organs, and selecting appropriate sites for cellular delivery.

The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.

Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.

The invention relates to the field of cell culture, in particular to cell cryopreservation liquid, application thereof and a cryopreservation method of megakaryocyte progenitor cells. The cell cryopreservation liquid comprises DMSO, fetal calf serum, dextran, trehalose and albumin. By means of the cell cryopreservation liquid, the cytoactive of the megakaryocyte progenitor cells can be well maintained during the cryopreservation period, and damage to cells in the cryopreservation and resuscitation processes is lowered. According to the cell cryopreservation liquid, application thereof and the cryopreservation method of the megakaryocyte progenitor cells, the cryopreservation and temperature reduction processes are softer, the cells are stored in liquid nitrogen after the temperature reduction process is conducted, the influence on the cytoactive is small, and damage to the cells in the cryopreservation process is lowered. It is indicated by experiments that the vigour of the resuscitated cells can reach 94% one month after the megakaryocyte progenitor cells are cryopreservated in the cryopreservation liquid, and multiplication activity is good, and the cell cryopreservation liquid is significantly superior to the prior art.

Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and / or oleuropein and chemotherapeutic agents are disclosed. Compositions and / or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.

A method of analyzing bubbles, cells, cell viability, or other particles or agglomerates in a process liquid contained in a vessel is provided. Images of bubbles, cells or other particles in the liquid are obtained in-situ with a vision probe extending through a wall of the vessel. The images are analyzed with image recognition software. The software measures at lease one of bubble, cell or particle size, mean diameter, surface area, flow rate, flow pattern, population distribution, viability, agglomerates or clumping, color change, viscosity, Sauter mean, ratio of surface area of bubbles relative to volume of bubbles, gas hold-up ratio of gas volume to volume of liquid, or interfacial area. The software distinguishes valid or viable bubbles, cells or particles that should be included in an analysis from invalid or non-viable bubbles, cells or particles that should not be included. The software can be configured to provide an analysis of the valid bubbles, cells or particles that fall within pre-set size and shape or viability parameters.

The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.

The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.

The invention discloses a serum-free animal origin-free culture medium for suspension culture of BHK-21 cells and a preparation method of the serum-free animal origin-free culture medium. According to the serum-free animal origin-free culture medium for suspension culture of the BHK-21 cells and the preparation method of the serum-free animal origin-free culture medium, through the addition and component optimization of amino acids, inorganic salt, vitamins, lipids, hydrolysates and the rest of additives in the culture medium, the multiplication speed of the BHK-21 cells is remarkably improved, the doubling time is shortened, and the high activity is maintained while the cells reach higher growth density. The culture medium is suitable for high-density suspension culture of the BHK-21 cells, low in cost, free of serum, free of animal origins and low in protein, the biological function of the serum is completely replaced through the addition of the ingredients including the lipids, the vitamins, the microelements, recombinant protein and the hydrolysates,, and some negative effects caused by the serum to later purification and separation of an antigen are avoided. Through optimization on the components of the culture medium, the multiplication speed of the BHK-21 cells in suspension culture is higher, the cell density is higher, the cell activity is higher, and the BHK-21 cells are more suitable for large-scale industrial production.

The present invention provides, in at least one embodiment, a loading device, system and method that loads aggregate cells into an encapsulation device for implanting into a patient. The loading system uses negative pressure from a low pressure pump in a closed system to improve safety and cell viability while allowing for even loading of the encapsulation device.

A novel electrically conductive polymer composite composed of polycaprolactone fumarate-polypyrrole (PCLF-PPy) for applications in nerve regeneration is disclosed. The synthesis and characterization of PCLF-PPy and in vitro studies showing PCLF-PPy supports both PC12 cell and Dorsal Root Ganglia neurite extension. PCLF-PPy composite materials were synthesized by polymerizing pyrrole in pre-formed scaffolds of PCLF resulting in an interpenetrating network of PCLF-PPy. PCLF-PPy composite materials possess electrical conductivity up to 6 mS cm−1 with compositions ranging from 5-13.5 percent polypyrrole of the bulk material. Surface topographies of PCLF-PPy materials show microstructures with a RMS roughness of 1195 nm and nanostructures with RMS roughness of 8 nm. PCLF-PPy derivatives were synthesized with anionic dopants to determine effects on electrical conductivity and to optimize the chemical composition for biocompatibility. In vitro studies using PC12 show PCLF-PPy composite materials induce a higher cellular viability and increased neurite extension compared to PCLF. PCLF-PPy composites doped with either naphthalene sulfonic acid or dodecyl benzene sulfonic acid are determined to be the optimal materials for electrical stimulation. In vitro studies showed significant increases in percentage of neurite bearing cells, number of neurites per cell and neurite length in the presence of ES compared to no ES. Additionally, extending neurites were observed to align in the direction of the applied current. Electrically conductive PCLF-PPy scaffolds possess material properties necessary for application as nerve conduits. Additionally, the capability to significantly enhance and direct neurite extension by passing electrical current through PCLF-PPy scaffolds renders them even more promising as future therapeutic treatments for severe nerve injuries.

The biological functionality of living microbial spores is modified using phenotypic engineering to endow the resulting modified spores with novel functionality that extends the usefulness of the spores for a variety of practical applications including, for example, sterility testing, the release of active compounds, and cell-based biosensing systems. A preferred embodiment entails engineering Bacillus spores to acquire synthetic new functions that enable the modified spores to sense and rapidly transduce specific germination signals in their surroundings. The newly acquired functions allow the spores to perform, for example, as self-reporters of cellular viability, self-indicating components of cell-based biosensors, and in other analytical systems.

The invention provides a method for in vitro induction and amplification of a human antigen nonspecific regulatory T cell. A human peripheral blood CD4<+> T cell with an abundant source is separated, and a CD4<+>CD25<-> T cell is induced and amplified into a CD4<+>CD25<+>CD127<dim> antigen nonspecific regulatory T cell with high purity and high regulation efficiency within a short period through a simple induction method meeting the Clinical Good Manufacturing Practice (GMP). An enough therapeutic dose of Treg can be obtained through induced cultivation of a week (6-7d), the phenotype and regulation function of the induced Treg are stable, furthermore, the incidence rate of events, such as cell activity reduction and microbial contamination due to long-term culture in vitro is greatly reduced, and the quality control method is specific and fast and is very suitable for clinical application.

The invention provides a stem cell preparation for treating hepatic fibrosis, and a preparation method of the stem cell preparation. The stem cell preparation for treating hepatic fibrosis is prepared from human menstrual blood mesenchymal stem cells, a chemotactic factor CXCL8 and normal saline. The obtaining method of the menstrual blood mesenchymal stem cells is simple, free of ethical restriction, high in cell viability and high in proliferation capacity, has multi-directional differentiation potential and is simple and convenient to prepare. The menstrual blood mesenchymal stem cell preparation infusion technology provided by the invention is simple and convenient to operate; the hepatic fibrosis is treated by virtue of the menstrual blood mesenchymal stem cells; and the developed preparation method of the stem cell preparation for treating the hepatic fibrosis has very important clinical significance and wide application prospect.

The invention discloses a serum-free and protein-free all-chemical-component-definition culture medium for supporting the CHO high-density suspension growth. The serum-free culture medium contains amino acids, inorganic salts, trace elements, vitamins, carbohydrates and other organic molecules. The serum-free culture medium has the advantages of no containment of any extracted or recombinant proteins, polypeptides or hydrolyzates, short cell growth time, high density, low metabolic refuse accumulation, good cell vitality maintenance, realization of the protein expression higher than that of products of same kind, and low cost because of all chemical component definition.

The present invention relates to a method, system and container apparatus that enables sustained cellular viability of tooth biology under hypothermic conditions while providing a matrix nutrient specific to teeth environment that autonomously prepares cells and tissues for the cryogenic freezing process, in vitro

The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product / Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss / cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C.

The invention relates to the technical field of biological pharmacy, in particular to preparation for a serum-free and animal-source-free culture medium suitable for an insect cell Sf-9. For the growth characteristic of the insect cell Sf-9, the low-cost, serum-free, animal-source-free and low-protein culture medium suitable for high-density suspension culture of the cell Sf-9 is developed. Components such as lipid, vitamins, microelement, recombinant protein, hydrolysate and the like are added to replace the biological function of serum, and some negative effects on later-stage purification and antigen separation from the serum are avoided. By optimizing the components of the culture medium, the proliferation speed of the cell Sf-9 in suspension culture is higher, cell density is higher, cell activity is higher, and the culture medium is more suitable for large-scale industrial production.

The invention provides an inducing culture method for regulatory T cells and relates to an inducing culture method for regulatory gamma delta T cells. In the method, cell factors are applied and deoxyribonucleic acid (DNA) demethylated medicament decitabine is combined so as to cooperatively induce the generation of the regulatory gamma delta T cells, and an enrichment process of magnetic cell sorter (MACS) positive sorting is adopted; after enrichment, detections of cell growth state and activity are carried out so as to ensure the next experience. The method has the advantages of simple and practicable inducing and enrichment processes, short period, low cost, high inducing efficiency and good repeatability; and after enrichment, cell activity is good, the quantity and activity of cells can ensure the next in vivo and in vitro studies, thereby providing a good study platform for defining the biological characteristics of the gamma delta T cells. Thus, the method has a good popularization value.

The invention discloses a separation method of human peripheral blood mononuclear cells. The separation method combines the advantages of a hydroxyethyl starch precipitation method and a Ficoll density gradient centrifugation method. The PBMC with a purity of greater than 95% and a vitality of greater than 85% is obtained by removing most of red blood cells by the hydroxyethyl starch precipitation method, then naturally settling in air, and then further purifying the mononuclear cells by the Ficoll density gradient centrifugation method, aiming at the separation characteristic of a high-capacity blood sample. Compared with a method without natural setting in air, the vitality and the purity of the cells obtained by the separation method are higher.

When a mutation, designated rad51M1, was generated in the mouse MmRAD51 gene, mutant embryos died shortly after implantation. rad51M1 cells exhibited hypersensitivity to ionizing radiation, reduced proliferation, programmed cell death and chromosome loss. The disruption of MmRad51 rotein-protein interactions stopped cell proliferation and / or reduced cell viability. Several proteins that interact with MmRad51 have been identified including, for example Brca2 and M96. Additionally, Rad51 self-associates via the N-terminal region. When a single residue was changed from a conserved lysine to an alanine, the alteration proved toxic to cells. Moreover, a rad51 allele that lacked the RecA homology region was also deleterious to cells. In view of the above, it is clear that inhibiting MmRad51 function or the function of any molecule that associates with MmRad51, or any molecule in the Rad51 or Rad52 pathways, hinders cell proliferation and / or viability. Accordingly, molecules capable of blocking these critical DNA repair pathways may be effective as therapeutics for inhibiting cell proliferation.

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and / or cell growth is reduced or eliminated.

This invention relates to methods for monitoring and controlling bioprocesses. Specifically, it describes using quasi-real-time analytical and numerical techniques to analyze optical loss measurements calibrated to indicate cell viability, whereby it is possible to reveal process changes and / or process events such as feeding or induction. Additionally, the present invention makes it possible to accurately estimate the onset of a decrease in cell viability and / or a suitable time for cell harvesting for a cell culture growth process. Pattern recognition methods for identifying specific process events such as batch feeding, cell infection, and product precipitation are also described.

A method is provided herein for indicating viability of cells grown on a rejection inert tissue cytoarchitecture or scaffolding with a medical device that supports at least one sensing function comprising:non-destructively observing a region of a patient to where cells have been transplanted;guiding the medical device to said region of a patient using the non-destructive observation;positioning said medical device within said region of a patient using the non-destructive observation to assist in the positioning;sensing a property within said region of a patient that is indicative of cell viability or nonviability; andusing data from sensing said property within said region to indicate cell viability from a transplant with the region. Magnetic Resonance Imaging is a particularly useful format for non-destructive observation of the region.

The invention relates to the technical field of cytobiology, in particular to an immune cell cryopreservation liquid and an immune cell cryopreservation method. The immune cell cryopreservation liquid comprises components as follows: 4-8 mL of dimethyl sulfoxide, 2-6 mL of dextran, 10-30 mL of a cell culture medium, 1-5 mL of human serum albumin and 60-100 mL of autologous plasm. The immune cell cryopreservation liquid can effectively protect immune cells from cryodamage, is high in safety, causes little damage to the cells and can increase recovery and survival rates of the immune cells, the survival rate after recovery can reach 96% or higher, besides, after recovery, cell viability is high, the multiplication number of the cells is large, the cells are not prone to aging, physiological functions and biological characteristics of the immune cells after recovery are guaranteed, microbiological detection indexes meet requirements, survival time of the immune cells is prolonged, and loss of surface antigens of the immune cells is reduced.